PURPOSE OF REVIEW: Recent studies demonstrate an increasing role for alloimmune responses in the disruption of self-tolerance leading to immune responses to self-antigens that play a role in the immunopathogenesis of chronic rejection following solid organ transplantation. This review summarizes recent studies and implications for the alloimmune-response-induced de-novo development of autoimmune responses following solid organ transplantations. RECENT FINDINGS: Immediately following organ transplantation, several factors lead to enduring an inflammatory milieu. Studies from our laboratory and others have demonstrated that development of antihuman leukocyte antigen antibodies precedes the development of chronic rejection. Using an in-vivo murine model, we have demonstrated that administration of anti-major histocompatibility complex (MHC) class I directly into the native lungs leads to chronic rejection pathology. Further, the in-vitro ligation of epithelial cell surface MHC class I molecules by specific anti-MHC can lead to cell activation and production of fibrinogenic growth factors. SUMMARY: On the basis of these findings, we hypothesized that alloimmune responses can lead to autoimmunity, thus playing an important role in chronic rejection. Characterization of both the temporal occurrence and functional significance of antibodies to self-antigens may provide insight into the pathogenesis of chronic rejection and these antibodies can serve as clinically useful biomarkers.
PURPOSE OF REVIEW: Recent studies demonstrate an increasing role for alloimmune responses in the disruption of self-tolerance leading to immune responses to self-antigens that play a role in the immunopathogenesis of chronic rejection following solid organ transplantation. This review summarizes recent studies and implications for the alloimmune-response-induced de-novo development of autoimmune responses following solid organ transplantations. RECENT FINDINGS: Immediately following organ transplantation, several factors lead to enduring an inflammatory milieu. Studies from our laboratory and others have demonstrated that development of antihuman leukocyte antigen antibodies precedes the development of chronic rejection. Using an in-vivo murine model, we have demonstrated that administration of anti-major histocompatibility complex (MHC) class I directly into the native lungs leads to chronic rejection pathology. Further, the in-vitro ligation of epithelial cell surface MHC class I molecules by specific anti-MHC can lead to cell activation and production of fibrinogenic growth factors. SUMMARY: On the basis of these findings, we hypothesized that alloimmune responses can lead to autoimmunity, thus playing an important role in chronic rejection. Characterization of both the temporal occurrence and functional significance of antibodies to self-antigens may provide insight into the pathogenesis of chronic rejection and these antibodies can serve as clinically useful biomarkers.
Authors: N Suciu-Foca; E Reed; C Marboe; P Harris; P X Yu; Y K Sun; E Ho; E Rose; K Reemtsma; D W King Journal: Transplantation Date: 1991-03 Impact factor: 4.939
Authors: N Suciu-Foca; E Reed; V D D'Agati; E Ho; D J Cohen; A I Benvenisty; R McCabe; J M Brensilver; D W King; M A Hardy Journal: Transplantation Date: 1991-03 Impact factor: 4.939
Authors: M Azizul Haque; Teruaki Mizobuchi; Kazuhiro Yasufuku; Takehiko Fujisawa; Randy R Brutkiewicz; Yan Zheng; Kena Woods; Gerald N Smith; Oscar W Cummings; Kathleen M Heidler; Janice S Blum; David S Wilkes Journal: J Immunol Date: 2002-08-01 Impact factor: 5.422
Authors: William J Burlingham; Robert B Love; Ewa Jankowska-Gan; Lynn D Haynes; Qingyong Xu; Joseph L Bobadilla; Keith C Meyer; Mary S Hayney; Ruedi K Braun; Daniel S Greenspan; Bagavathi Gopalakrishnan; Junchao Cai; David D Brand; Shigetoshi Yoshida; Oscar W Cummings; David S Wilkes Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: V Tiriveedhi; M Takenaka; S Ramachandran; A E Gelman; V Subramanian; G A Patterson; T Mohanakumar Journal: Am J Transplant Date: 2012-07-23 Impact factor: 8.086
Authors: V Tiriveedhi; N Angaswamy; D Brand; J Weber; A G Gelman; R Hachem; E P Trulock; B Meyers; G Patterson; T Mohanakumar Journal: Clin Exp Immunol Date: 2012-01 Impact factor: 4.330